open access
Nivolumab in treatment of renal cell carcinoma during renal replacement therapy
Affiliations- Department of Oncology, University Hospital in Cracow
open access
Abstract
The prolongation of overall survival of advanced RCC patients requires the use of modern therapies including tyrosine kinase inhibitors and immune checkpoint inhibitors. Although these drugs have different pharmacokinetics, preclinical studies rarely indicate significant renal clearance. To date there has been a lack of prospective studies evaluating their efficacy and safety in end-stage renal disease patients undergoing dialysis. This case study describes second-line treatment of RCC with nivolumab in a dialysed patient following bilateral nephrectomy.
Abstract
The prolongation of overall survival of advanced RCC patients requires the use of modern therapies including tyrosine kinase inhibitors and immune checkpoint inhibitors. Although these drugs have different pharmacokinetics, preclinical studies rarely indicate significant renal clearance. To date there has been a lack of prospective studies evaluating their efficacy and safety in end-stage renal disease patients undergoing dialysis. This case study describes second-line treatment of RCC with nivolumab in a dialysed patient following bilateral nephrectomy.
Keywords
kidney cancer, nivolumab, dialysis
About this articleTitle
Nivolumab in treatment of renal cell carcinoma during renal replacement therapy
Journal
Issue
Article type
Case report
Published online
2019-04-16
Page views
376
Article views/downloads
457
DOI
10.5603/OCP.2018.0039
Bibliographic record
Oncol Clin Pract 2019;15(1).
Keywords
kidney cancer
nivolumab
dialysis
Authors
Kamil Konopka
References (3)- Markić D, Valencić M, Spanjol J, et al. Renal function outcomes after nephrectomy for kidney cancer in elderly patients. Coll Antropol. 2011; 35 Suppl 2: 121–124.
- Motzer RJ, Escudier B, McDermott DF, et al. CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19): 1803–1813.
- Bajaj G, Wang X, Agrawal S, et al. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017; 6(1): 58–66.